Our strength is in our breadth
new study from the University of Sydney’s Lambert Initiative
Are blood and oral fluid Δ9-tetrahydrocannabinol (THC) and metabolite concentrations related to impairment? A meta-regression analysis
Highlights:
- THC-related biomarkers were associated with impairment in occasional cannabis users.
- However, most of these ‘biomarker–performance’ relationships were ‘weak’ in strength.
- THC-related biomarkers were not associated with impairment in regular cannabis users.
- THC-related biomarkers are relatively poor indicators of cannabis-induced impairment.
Published in Neuroscience & Biobehavioral Reviews
International JOURNAL OF DRUG POLICY (Volume 97, Nov 2021)
Medicinal cannabis and driving: the intersection of health and road safety policy
Background
Recent shifting attitudes towards the medical use of cannabis has seen legal access pathways established in many jurisdictions in North America, Europe and Australasia. However, the positioning of cannabis as a legitimate medical product produces some tensions with other regulatory frameworks. A notable example of this is the so-called ‘zero tolerance’ drug driving legal frameworks, which criminalise the presence of THC (tetrahydrocannabinol) in a driver's bodily fluids irrespective of impairment. Here we undertake an analysis of this policy issue based on a case study of the introduction of medicinal cannabis in Australia.
Conclusion
We conclude that in medical-only access models there is little evidence to justify the differential treatment of medicinal cannabis patients, compared with those taking other prescription medications with potentially impairing effects.
Click picture to see full abstract
